Education
About Us
Working with TipRanks
Follow Us
Marinus Pharmaceuticals Inc (MRNS)
NASDAQ:MRNS
MRNS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.22 - $10.50
Previous CloseN/A
Volume358.63K
Average Volume (3M)2.50M
Market Cap
$30.37M
Enterprise Value$153.73M
Total Cash (Recent Filing)$67.73M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.13
Next Earnings
Mar 11, 2025EPS Estimate
-0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.47
Shares Outstanding53,869,000
10 Day Avg. Volume723,919
30 Day Avg. Volume2,497,443
Standard Deviation0.28
R-Squared0.04
Alpha-0.00113
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.96
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap5.06
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.29
Enterprise Value/Ebitda-1.25
Forecast
1Y Price Target
$0.95Price Target Upside72.73% Upside
Rating ConsensusHold
Number of Analyst Covering3
---
Marinus News
PremiumCompany Announcements
Immedica Pharma Completes Acquisition of Marinus Pharmaceuticals
PremiumCompany Announcements
Marinus Ends Agreements Amid Strategic Review
PremiumCompany Announcements
Marinus Pharmaceuticals Merges with Immedica Pharma AB
PremiumCompany Announcements
Marinus Unveils Management Retention and Severance PlansPremiumCompany Announcements
Marinus Pharmaceuticals Faces Financial Turmoil Amidst Class Action Lawsuit---
Bulls Say, Bears Say
Bulls Say
Potential PartnershipsThere is potential for a partner or acquirer for ZTALMY given its established launch success in patients with CDKL5-deficiency disorder.
Product ApprovalZtalmy (oral ganaxolone) is approved in several countries as the only treatment for CDKL5 deficiency disorder.
Revenue GrowthZtalmy performance was solid with Q3 2024 net product revenue of $8.5 million, up 56% year-over-year.
Bears Say
Clinical Trial ResultsThe Ph. III trial of ganaxolone in TSC failed to meet the primary endpoint.
Financial PerformanceMarinus reported a Q3 net loss of $24.2MM or $0.42/share.
Revenue GuidanceManagement tweaked down guidance for the full year 2024 to $33-34 million from $33-35 million, reflecting modest patient additions.
---
Ownership Overview
1.34% Insiders
6.05% Mutual Funds
0.11% Other Institutional Investors
89.23% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MRNS FAQ
What was Marinus Pharmaceuticals Inc’s price range in the past 12 months?
Marinus Pharmaceuticals Inc lowest stock price was $0.22 and its highest was $10.50 in the past 12 months.
What is Marinus Pharmaceuticals Inc’s market cap?
Marinus Pharmaceuticals Inc’s market cap is $30.37M.
When is Marinus Pharmaceuticals Inc’s upcoming earnings report date?
Marinus Pharmaceuticals Inc’s upcoming earnings report date is Mar 11, 2025 which is in 7 days.
How were Marinus Pharmaceuticals Inc’s earnings last quarter?
Marinus Pharmaceuticals Inc released its earnings results on Nov 12, 2024. The company reported -$0.42 earnings per share for the quarter, missing the consensus estimate of -$0.409 by -$0.011.
Is Marinus Pharmaceuticals Inc overvalued?
According to Wall Street analysts Marinus Pharmaceuticals Inc’s price is currently Undervalued.
Does Marinus Pharmaceuticals Inc pay dividends?
Marinus Pharmaceuticals Inc does not currently pay dividends.
What is Marinus Pharmaceuticals Inc’s EPS estimate?
Marinus Pharmaceuticals Inc’s EPS estimate is -0.33.
How many shares outstanding does Marinus Pharmaceuticals Inc have?
Marinus Pharmaceuticals Inc has 53,869,000 shares outstanding.
What happened to Marinus Pharmaceuticals Inc’s price movement after its last earnings report?
Marinus Pharmaceuticals Inc reported an EPS of -$0.42 in its last earnings report, missing expectations of -$0.409. Following the earnings report the stock price went down -11.765%.
Which hedge fund is a major shareholder of Marinus Pharmaceuticals Inc?
Among the largest hedge funds holding Marinus Pharmaceuticals Inc’s share is Woodline Partners LP. It holds Marinus Pharmaceuticals Inc’s shares valued at 2M.
---
Marinus Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$0.95 (72.73% Upside)
$0.95 (72.73% Upside)
Blogger Sentiment
Neutral
MRNS Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
―
20 days / 200 days
Momentum
-94.50%
12-Months-Change
Fundamentals
Return on Equity
210.50%
Trailing 12-Months
Asset Growth
-68.32%
Trailing 12-Months
Company Description
Marinus Pharmaceuticals Inc
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid. The company was founded by Geoffrey E. Chaiken, Harry H. Penner Jr., Vincent A. Pieribone and Kenneth R. Shaw on August 14, 2003 and is headquartered in Radnor, PA.
---
MRNS Stock 12 Month Forecast
Average Price Target
$0.95
▲(72.73% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Catalyst Pharma
―
Sarepta Therapeutics
―
PTC Therapeutics
―
SAGE Therapeutics
―
Best Analysts Covering MRNS
1 Year
1 Year Success Rate
5/12 ratings generated profit
1 Year Average Return
+5.37%
reiterated a buy rating 4 months ago
Copying Jay Olson's trades and holding each position for 1 Year would result in 41.67% of your transactions generating a profit, with an average return of +5.37% per trade.
---